1/3 of Europeans are over 55 years old, when conditions such as eudiometrical cancer, vaginal dryness, benign prostates hyperplasic, prostrate cancer and urinary incontinence are common, with increased healthcare costs and reduction in quality of life and mobility. The lack of oestrogens appears causally linked to the development and progress of such diseases. (E) UROESTROGEN (E) S aims to promote the development of selective estrogens receptor modulators (Serums) with reference to phyto-SERMs. 5 partners at 4 universities belong to the European thematic network EUROSTERONE, with excellent laboratory infrastructure and access to patients. The research will lead to concepts for clinical trial and well-tolerated phyto-SERMs beneficial in the human argental tract. This will both aid the ageing population, and be of great socio-economic impact throughout Europe.